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Abstract
Background: This study sought to investigate crucial genes correlated with diabetic nephropathy (DN), and their
potential functions, which might contribute to a better understanding of DN pathogenesis.
Methods: The microarray dataset GSE1009 was downloaded from Gene Expression Omnibus, including 3 diabetic
glomeruli samples and 3 healthy glomeruli samples. The differentially expressed genes (DEGs) were identified by
LIMMA package. Their potential functions were then analyzed by the GO and KEGG pathway enrichment analyses
using the DAVID database. Furthermore, miRNAs and transcription factors (TFs) regulating DEGs were predicted by
the GeneCoDis tool, and miRNA-DEG-TF regulatory network was visualized by Cytoscape. Additionally, the
expression of DEGs was validated using another microarray dataset GSE30528.
Results: Totally, 14 up-regulated DEGs and 430 down-regulated ones were identified. Some DEGs (e.g. MTSS1,
CALD1 and ACTN4) were markedly relative to cytoskeleton organization. Besides, some other ones were correlated
with arrhythmogenic right ventricular cardiomyopathy (e.g. ACTN4, CTNNA1 and ITGB5), as well as complement and
coagulation cascades (e.g. C1R and C1S). Furthermore, a series of miRNAs and TFs modulating DEGs were identified.
The transcription factor LEF1 regulated the majority of DEGs, such as ITGB5, CALD1 and C1S. Hsa-miR-33a modulated
28 genes, such as C1S. Additionally, 143 DEGs (one upregulated gene and 142 downregulated genes) were also
differentially expressed in another dataset GSE30528.
Conclusions: The genes involved in cytoskeleton organization, cardiomyopathy, as well as complement and
coagulation cascades may be closely implicated in the progression of DN, via the regulation of miRNAs and TFs.
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Background
Diabetic nephropathy (DN) is a complication correlated
with both type 1 and type 2 diabetes and is characterized
by glomerulosclerosis due to accumulation of extracellu-
lar matrix [1]. Despite great attention from both clini-
cians and basic scientists, the morbidity of end-stage
renal disease and glomerulosclerosis in diabetic patients
is increasing dramatically [2].
In the past years, many molecules associated with DN
have been uncovered. For example, the mammalian target
of rapamycin (mTOR) complex 1 activation has a key role
in podocyte dysfunction in diabetic mice [3, 4]. Rooney et
al. have shown that connective tissue growth factor/CCN
family protein 2 (CTGF/CCN2) can activate the Wnt sig-
naling in mesangial cells through low density lipoprotein
receptor-related protein 6 (LRP6), which may be impli-
cated in the pathogenesis of DN [5]. In diabetic mice,
Glo1 (Glyoxalase 1) overexpression completely inhibits
diabetes-induced increases in methylglyoxal modification
of glomerular proteins, and promotes the development of
diabetic kidney disease (DKD) [6]. Furthermore, there is
evidence that miR-192 enhances collagen expression by
regulating the E-box repressors Zeb1/2, and locked nu-
cleic acid–anti-miR-192 alleviates proteinuria in the dia-
betic mice [7]. Based on a gene expression profiling of
DN, Hans et al. have shown that some genes in glomeruli
from patients with DN are down-regulated, such as bone
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morphogenetic protein 2, fibroblast growth factor 1, vas-
cular endothelial growth factor, nephrin and insulin-like
growth factor binding protein 2, suggesting that progres-
sion of DN might be due to diminished tissue repair abil-
ity [8]. However, the pathways which the differentially
expressed genes (DEGs) participate in and regulators that
target these genes remain unknown.
In this study, the microarray dataset GSE1009 depos-
ited by Hans [8] was used to identify DEGs between
diabetic glomeruli samples and healthy controls. Gene
Ontology (GO) and pathway enrichment analyses were
then performed for the up- and down-regulated DEGs.
Furthermore, microRNAs (miRNAs) and transcription
factors (TFs) regulating DEGs were predicted, and
miRNA-DEG-TF regulatory network was constructed.
These findings may contribute to a better understanding
of the nosogenesis of DN.
Methods
Affymetrix microarray data
The gene expression profile data of GSE1009 [8] were
downloaded from the public database Gene Expression
Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/), which
was based on the platform of [HG_U95Av2] Affymetrix
Human Genome U95 Version 2 Array (GPL8300, Affyme-
trix Inc., Santa Clara, California, USA). This dataset con-
tained 6 glomeruli samples, including 3 samples from 2
kidneys from patients with diabetes mellitus type 2, and 3
samples from 2 healthy kidneys.
Another gene expression dataset GSE30528 [9] in
GEO, which contains a relatively big sample size and has
a high data quality, was used for validation. The data in
GSE30528 were produced by the platform of [HG-
U133A_2] Affymetrix Human Genome U133A 2.0 Array
(GPL571, Affymetrix Inc., Santa Clara, California, USA).
A total of 9 diabetic glomeruli samples from patients
with DKD and 13 healthy glomeruli samples were in-
cluded in this dataset.
CEL files and the probe annotation files were downloaded,
and the gene expression data of all samples were prepro-
cessed via background correction, quantile normalization
and probe summarization using the Robust Multi-array
Average (RMA) algorithm in Affy software package of
Bioconductor (available at http://www.bioconductor.org/
packages/release/bioc/html/affy.html) [10].
DEGs screening
Linear Models for Microarray Data (LIMMA) package [11]
of Bioconductor (available at http://www.bioconductor.org/
packages/release/bioc/html/limma.html) was used to iden-
tify genes that were differentially expressed in diabetic
glomeruli. Only the genes meeting p-value < 0.05 and
|log2FC (fold change)| ≥ 1 were chosen as DEGs.
Enrichment analysis for DEGs
To explore the functions of DEGs in diabetic glomeruli sam-
ples, the DAVID (Database for Annotation, Visualization
and Integrated Discovery) database [12] was used to
perform GO and KEGG (Kyoto Encyclopedia of
Genes and Genomes) pathway enrichment analyses
for DEGs. The p-value < 0.01 and gene count ≥ 2 were
set as the cut-off criteria.
Furthermore, the category of enriched GO terms and
the gene number were displayed as a histogram which
was constructed by WEGO (Web Gene Ontology Anno-
tation Plot) [13] with the cut-off criterion of level = 2.
Construction of miRNA-DEG-TF regulatory network
GeneCoDis (Gene Annotation Co-occurrence Discovery,
http://genecodis.cnb.csic.es/) [14], which is a grid-based
tool that integrates biological information from different
sources to search for biological characteristics (annota-
tions) that frequently co-occur in a series of genes and
rank them by statistical significance, was used to identify
miRNAs and TFs regulating DEGs with hypergeometric
algorithm, and the adjusted p-value < 0.01 was used as
the cut-off criteria. The regulatory network consisting of
DEGs, miRNAs and TFs were then visualized by Cytos-
cape (http://cytoscape.org/) [15].
Validation of the expression level of DEGs
The DEGs between DN and control samples in the dataset
GSE30528 were identified using the aforementioned
methods. The overlapped DEGs in both of GSE30528 and
GSE1009 were then identified using the VennDiagram
package. Here, if a gene was differentially expressed in
both of GSE30528 and GSE1009 with the same expression
pattern (up-regulated or down-regulated expression), this
gene was identified as an overlapped DEG.
Results
Identification of DEGs
Based on the cut-off criteria, a set of 444 genes were identi-
fied to be differentially expressed in the diabetic glomeruli
samples, including 14 up-regulated and 430 down-regulated
ones, compared with the controls (Additional file 1).
GO and KEGG pathway enrichment analysis of up- and
down-regulated DEGs
A total of 111 GO terms for the down-regulated DEGs
were generated. Some genes (e.g. MTSS1, CALD1 and
ACTN4) were related to cytoskeleton organization, such
as actin filament-based process, actin cytoskeleton and
cytoskeletal protein binding; some other genes were dis-
tinctly enriched in negative regulation of cell proliferation
(e.g. AIF1, IGFBP7 and COL4A3) (Table 1). Using WEGO
(level = 2), 25 categories of GO terms for down-regulated
DEGs were displayed. The majority of genes were enriched
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in biological processes (BP), such as anatomical structure
formation, biological regulation, death and response to
stimulus. Moreover, several GO terms in cellular compo-
nent (CC) were obtained, such as cell part and organelle.
Furthermore, three GO terms in molecular function (MF)
were enriched by the down-regulated genes, including
binding, structural molecule and transporter (Fig. 1). In
addition, three up-regulated DEGs (CD69, LGALS2 and
FBP1) were significantly enriched in sugar binding.
According to KEGG enrichment analysis, the down-
regulated DEGs were significantly enriched in 6 pathways,
such as arrhythmogenic right ventricular cardiomyopathy
(ARVC) (e.g. ACTN4, CTNNA1 and ITGB5), regulation of
actin cytoskeleton (e.g. ACTN4, MYL9 and ITGB5) and
complement and coagulation cascades (e.g. C1R and C1S).
There were no significant pathways for the up-regulated
DEGs (Table 2).
Analysis of miRNA-DEG-TF regulatory network
Totally, 896 regulatory relationships between miRNAs,
TFs and DEGs were identified to construct the miRNA-
DEG-TF regulatory network, including 24 miRNAs, 44
TFs and 275 down-regulated genes (Fig. 2). The
transcription factor LEF1 regulated most of genes (degree
= 79), such as ITGB5, CALD1, RTN4 and PAK1. Hsa-miR-
33a modulated 28 genes, such as C1S and RTN4.
Besides, no miRNAs were predicted to regulate the up-
regulated genes, whereas, two TFs (AML1 and NFKB)
were identified to modulate several up-regulated genes.
Among them, AML1 regulated CD96 and CYP17A1.
Screening of overlapped DEGs in the two datasets
To validate the expression of the identified DEGs in the
dataset GSE1009, another dataset GSE30528 was used.
A total of 635 DEGs were identified in GSE30528.
Among them, 143 DEGs, including one upregulated
gene (TRIM16) and 142 downregulated genes (e.g.
MTSS1, ACTN4 and ITGB5), were also differentially
expressed in the dataset GSE1009 (Fig. 3), indicating that
the expression of the 143 DEGs in GSE1009 identified
above were validated by the dataset GSE30528.
Discussion
In the present study, a set of 444 DEGs in the dataset
GSE1009 were identified from diabetic glomeruli samples,
including 14 up-regulated ones and 430 down-regulated
Table 1 The top 5 enriched GO terms with the most low p-value for differentially expressed genes
Category Terms Description Count p-value Genes
BP GO:0030029 actin filament-based process 23 5.38E-07 MTSS1, ROCK1, ACTN4, AIF1, CALD1, ARF6, MYH9, CAPZB, TNNT2,
ACTG1…
GO:0030036 actin cytoskeleton organization 22 7.32E-07 MTSS1, ROCK1, ACTN4, AIF1, CALD1, ARPC5, MYH9, CAPZB, TNNT2,
ACTG1…
GO:0008285 negative regulation of cell proliferation 28 1.48E-06 AIF1, IGFBP7, PTH1R, ING1, COL4A3, BMP2, CTBP1, GAS1, CD164,
TGFBR3…
GO:0007010 cytoskeleton organization 31 2.17E-06 MTSS1, AIF1, CALD1, ARF6, ACTG1, PAK1, PLS3, ACTN4, ROCK1,
MYH9…
GO:0030832 regulation of actin filament length 11 6.01E-06 ACTR3, PFN2, CAPZA1, TMSB4X, RDX, ARF6, ARPC5, CAPZB, SPTAN1,
DSTN…
CC GO:0015629 actin cytoskeleton 31 2.60E-11 MTSS1, AIF1, CALD1, MYL9, ACTR3, ACTG1, ACTN4, MYO1B, MYH9,
CTNNA1…
GO:0005938 cell cortex 20 1.02E-08 SEPT2, ACTN4, SEPT1, CALD1, ARF6, MYH9, SEPT10, ACTG1, FNBP1,
CLIC5…
GO:0005856 cytoskeleton 70 1.28E-07 MTSS1, AIF1, CALD1, MYL9, ACTR3, ACTG1, ACTN4, MYO1B, MYH9,
CTNNA1…




104 5.54E-06 SEPT2, ACTN4, SEPT1, CALD1, PRKCI, MYH9, CAPZB, SEPT10, DSTN,
ACTG1…
MF GO:0008092 cytoskeletal protein binding 40 7.17E-10 MTSS1, AIF1, TNNC1, CALD1, EZR, TARDBP, ACTN4, MYO1B, SUN2,
MYH9…
GO:0003779 actin binding 30 5.79E-09 MTSS1, AIF1, TNNC1, CALD1, ACTN4, MYH9, PALLD, NEBL, TNNT2,
PARVA…
GO:0005520 insulin-like growth factor binding 6 3.80E-04 CTGF, HTRA1, IGFBP7, IGFBP2, CRIM1, CYR61
GO:0005200 structural constituent of cytoskeleton 9 6.07E-04 TNNT2, ACTG1, DMD, VIM, AGRN, ARPC5, CD2AP, ADD3, SPTAN1
GO:0050839 cell adhesion molecule binding 6 9.18E-04 EZR, PVRL2, NPTN, CTNNA1, CD2AP, CTNNB1
GO Gene Ontology, BP biological process, MF molecular function, CC cellular component
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ones, compared with healthy glomeruli samples. Among
them, the expression of 143 DEGs (one upregulated gene
and 142 downregulated genes) were validated by another
dataset GSE30528. According to the GO functional en-
richment analysis, a set of DEGs were related to the func-
tion of cytoskeleton organization, such as MTSS1, ACTN4
and CALD1.
MTSS1 encodes metastasis suppressor 1, which is also
known as MIM (missing in metastasis). It is an actin and
membrane binding protein that was originally identified
as a potential tumor metastasis suppressor [16]. MTSS1
can induce actin-rich protrusions at the plasmalemma
and promote disintegration of actin stress fibers [17], in-
dicating that it may be crucial in regulating cytoskeletal
dynamics. Renal tubular cell and podocyte apoptosis is
an inevitable event in the progression of glomerulo-
sclerosis [18, 19], and major modifications of the cyto-
skeleton are involved in the apoptosis progress,
including dynamic membrane blebbing, nuclear disinte-
gration, chromatin condensation and cell fragmentation
[20]. Therefore, MTSS1 may play a pivotal role in DN,
via participation in the regulation of cytoskeleton
organization. ACTN4 encodes an actinin, which partici-
pates in cytoskeleton action. Previous studies have been
reported that mutations in ACTN4 cause focal segmental
glomerulosclerosis [21–23]. There is evidence that two
single-nucleotide polymorphisms in ACTN4 are associ-
ated with DN in women [24]. Moreover, the up-
regulation of ACTN4 was observed during the protein-
uria stage [25]. Thereby, ACTN4 may be also important
in the progression of DN. CALD1 encodes a caldesmon
that plays a key role in the regulation of smooth muscle
and nonmuscle contraction [26]. A previous study has
shown that CALD1 is over-expressed in fibroblasts from
the diabetic patients with nephropathy, compared with
those from the controls [27]. Conway et al. have
Fig. 1 The histogram of the category of enriched GO (Gene Ontology) terms for the down-regulated genes. CC represents cellular component;
MF represents molecular function; and BP represents biological process. WEGO represents the tool Web Gene Ontology Annotation Plot
Table 2 The results of pathway enrichment analysis for the down-regulated genes
Category Pathway Name Count p-value Genes
KEGG_PATHWAY Arrhythmogenic right ventricular
cardiomyopathy (ARVC)
11 1.41E-04 ACTG1, ATP2A2, ACTN4, DMD, DAG1, CACNB2, ITGB5, ITGA3,
CTNNA1, CTNNB1…
ACTN4, ROCK1, ITGB5, RDX, ITGA3, ARPC5, MYL12A, MYH9, MYL9,
ACTG1…KEGG_PATHWAY Regulation of actin cytoskeleton 19 1.65E-04
KEGG_PATHWAY Hypertrophic cardiomyopathy (HCM) 9 0.00575 TNNT2, ACTG1, ATP2A2, TNNC1, DMD, DAG1, CACNB2, ITGB5,
ITGA3
KEGG_PATHWAY Complement and coagulation cascades 8 0.00641 CD55, F3, CD46, CD59, C1R, SERPING1, C1S, F2R
KEGG_PATHWAY Dilated cardiomyopathy 9 0.00920 TNNT2, ACTG1, ATP2A2, TNNC1, DMD, DAG1, CACNB2, ITGB5,
ITGA3
KEGG_PATHWAY Pathogenic Escherichia coli infection 7 0.00956 ACTG1, EZR, ROCK1, TUBB2A, YWHAQ, ARPC5, CTNNB1
KEGG, Kyoto Encyclopedia of Genes and Genomes
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demonstrated that caldesmon is a candidate susceptibil-
ity gene for DN [28]. In this study, CALD1 was found to
be regulated by several TFs, such as LEF1. LEF1 (lymph-
oid enhancer-binding factor 1) is a nuclear transcription
factor modulated by Wnt, and it expedites epithelial to
mesenchymal transition (EMT) when its activity is
activated by β-catenin [29]. Rooney et al. have reported
that overexpression of CCN2 during the progression of
DN likely results in the activation of Wnt signaling and
subsequent initiation of TCF/LEF transcription [5].
Collectively, CALD1 may play an essential role in the
development of DN likely through the regulation of LEF1.
Furthermore, a series of downregulated DEGs were dis-
covered to be enriched in the pathways of arrhythmogenic
right ventricular cardiomyopathy and hypertrophic cardio-
myopathy in our study, such as ITGB5. Diabetic cardio-
myopathy is a frequent event in diabetic patients due to
hyperglycemia [30]. ITGB5 encodes integrin beta 5 [31],
and it has been found to be differentially expressed in
DKD glomeruli and tubuli [9]. Furthermore, integrins are
the primary receptors for intercellular adhesion molecule
1 (ICAM1), which has been reported to have a close rela-
tionship with DN [32]. Additionally, in our study, ITGB5
was also regulated by LEF1. These results suggest that
ITGB5 may have a significant function in the development
of DN, via participating in cardiomyopathy pathways.
Additionally, a set of genes were markedly enriched in
complement and coagulation cascades, such as C1S and
C1R. These two genes both encode members of the hu-
man complement subcomponent C1, which is involved
in immune response [33]. Migration of immune cells
into the renal is a feature of early DN, and it is impli-
cated in the development of this complication [34–37].
Previous studies also have found C1S and C1R to be dif-
ferentially expressed in DN [38, 39]. In our study, C1S
and C1R were regulated by LEF1 and hsa-miR-33a. MiR-
33a has been reported to be implicated in diabetes due
to its regulation of insulin signaling and fatty acid me-
tabolism [40, 41]. Therefore, C1S and C1R may be cru-
cial in the development of DN.
However, this study has some limitations. For example,
these predictions were not validated by experiments.
Fig. 2 The network consisting of differentially expressed genes, microRNAs and transcription factors. Rounded nodes represent genes; trigonal
nodes represent microRNAs; and quadrate nodes represent transcription factors
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The number of samples used for analysis is small. In
further studies, more samples will be analyzed, and the
predictions will be validated by experimental data.
Conclusion
In conclusion, a total of 14 up-regulated genes and 430
down-regulated ones were identified. Some DEGs related
to cytoskeleton organization (e.g. MTSS1, ACTN4 and
CALD1), cardiomyopathy (e.g. ITGB5) and immune re-
sponse (e.g. C1S and C1R), as well as some regulators
(e.g. LEF1 and hsa-miR-33a) might play pivotal roles in
the progression of DN. These findings may contribute to
our better understanding of DN pathogenesis, and pro-
vide a theoretical basis for further experimental studies.
Additional file
Additional file 1: The list of differentially expressed genes. (XLSX 30 kb)
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